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Idiopathic hemihypertrophy (IH) is a congenital overgrowth syndrome associated with an increased risk of em-
bryonal cancers in childhood. A related developmental disorder is Beckwith-Wiedemann syndrome (BWS), which
increases risk for embryonal cancers, including Wilms tumor. Constitutional epigenetic alterations associated with
BWS have been well characterized and include epigenetic alterations of imprinted genes on 11p15. The frequency
of hypermethylation of H19 in children with IH and Wilms tumor, 20% (3/15), was signiﬁcantly lower than the
frequency in children with BWS and Wilms tumor, 79% (11/14; P p .0028). These results indicate that children
with IH and Wilms tumor have different constitutional epigenotypes from those of children with BWS and Wilms
tumor.
Idiopathic hemihypertrophy (IH [MIM 235000]) is a
congenital overgrowth syndrome associated with an
increased risk of embryonal cancers of childhood, in-
cluding Wilms tumor (Hoyme et al. 1998). A related
congenital overgrowth and cancer-predisposition syn-
drome is Beckwith-Wiedemann syndrome (BWS [MIM
#130650]). BWS is also associated with hemihyperplasia
and embryonal cancers of childhood, including Wilms
tumor (DeBaun and Tucker 1998); however, there are
many other manifestations, such as macroglossia, ab-
dominal-wall defects (omphalocele, diastasis recti, or
umbilical hernia), and neonatal hypoglycemia. In chil-
dren with BWS, Wilms tumor is primarily associated
with constitutive hypermethylation of theH19 promoter
and loss of imprinting of IGF2; in a case-cohort study
of children with BWS, constitutional hypermethylation
of H19 was associated with a fourfold greater risk of
embryonal cancers than that in childrenwith othermeth-
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ylation abnormalities (DeBaun et al. 2002). In contrast
to BWS, only uniparental disomy (UPD) of 11p15 has
been associated with cancer in children with IH. Despite
the similarities between these two syndromes, limited
molecular data exist as to whether BWS and IH represent
phenotype variations of the same genotype or, in fact,
are two separate syndromes with different genotypes. To
test the hypothesis that children with BWS and IH have
the same genotype with variable expression, we per-
formed genotype-phenotype studies in children identiﬁed
as having IH or BWS and Wilms tumor from the Na-
tional Wilms Tumor Study (NWTS).
Patients in the study were registered in NWTS 3 and
4; the design of NWTS has been reported elsewhere
(Breslow et al. 1988). At the time of enrollment, regis-
tering physicians were requested to indicate the presence
or absence of speciﬁc conditions, including BWS and IH.
No systematically collected details about the clinical fea-
tures of IH and BWS in the patients were available. A
pediatric oncologist with expertise in evaluating children
with overgrowth syndromes reviewed all records. All
classiﬁcations of either IH or BWS were done prior to
and independent of genetic analyses.
Patients with either BWS or IH and fresh frozen tissues
submitted to the NWTS Wilms tumor bank were iden-
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Figure 1 Analysis of H19 methylation in patients with BWS and
IH. A 1.0-kb fragment of the H19 gene was hybridized to genomic
DNA digested with PstI and the methylcytosine-sensitive restriction
enzyme SmaI. The upper band represents the 1.8-kb methylated frag-
ment, and the lower band represents the 1.0-kb unmethylated digested
fragment. Patient numbers corresponding to those in the tables are
shown below the lanes. All DNA specimens were from the normal
kidney. fk p fetal kidney.
Table 1
Clinical Features of Patients with BWS
Patient
Birth
Weighta,b
(kg) Congenital Anomalies Noted in Chartb
BWS1 4.5 BWS
BWS2 4.7 BWS, somatic overgrowth
BWS3 3.9 BWS
BWS4 4.3 BWS, macroglossia, hemihypertrophy, adrenal
adenoma
BWS5 4.7 BWS
BWS6 3.2 BWS, hemihypertrophy
BWS7 2.4 BWS, omphalocele
BWS8 3.5 BWS, macroglossia, hemihypertrophy, umbilical
hernia, cryptorchidism
BWS9 NA BWS, hemihypertrophy
BWS10 NA Accessory renal artery
BWS11 NA None
BWS12 NA Accessory renal artery
BWS13 NA Accessory renal artery, 4th and 5th anterior rib
anomalies
BWS14 NA Hemihypertrophy
BWS15 NA NA
BWS16 NA NA
a Gestational ages were not available; however, at 40 wk gestational
age, the 90th percentile for birth weight is ∼3.9 kg, and the 50th
percentile is ∼3.4 kg (Oken et al. 2003).
b NA p not available.
tiﬁed and represent the sampling frame. Frozen aliquots
of all these samples were then selected for analysis. Con-
trol samples of Wilms tumors from nonsyndromic pa-
tients were similarly obtained.
Genomic DNA was prepared from snap-frozen nor-
mal kidney tissue, tumor tissue, and peripheral blood
lymphocytes by standard proteinase K digestion and
phenol extraction (Cui et al. 1998).H19 andLIT1meth-
ylation and UPD analysis by microsatellite marker typ-
ing were done as described elsewhere (DeBaun et al.
2002). Loss of heterozygosity (LOH) analysis was per-
formed similar to UPD analysis by use of FAM-labeled
primer pairs, detection on a model 377 automated ﬂuo-
rescent DNA sequencer (Applied Biosystems), and anal-
ysis with Genescan and Genotyper software (Applied
Biosystems). Examination of the chromatograms from
samples with UPD revealed a small peak (!20% of the
expected size), corresponding to the lost allele and
thereby indicating mosaicism for UPD. Patients in whose
DNA an allele was reduced in the tumor tissue compared
with the normal tissue were considered to have LOH.
The threshold for LOH by visual chromatogram in-
spection was 50%.
Abnormal methylation of H19 in kidney was deﬁned
as a methylation index 10.74 (mean  2 SD of six kid-
ney samples from control Wilms tumors with intralobar
nephrogenic rests, the histological subtype of Wilms tu-
mor not associated with epigenetic alterations of H19
and IGF2 [Ravenel et al. 2001]). Abnormal methylation
of H19 in lymphocytes was deﬁned as a methylation
index 10.63 (mean  2 SD of 15 normal individuals).
Abnormal methylation of LIT1 in kidney and lympho-
cytes was deﬁned as a methylation index !0.39 (mean
 2 SD of six kidney samples from controlWilms tumors
and of 15 normal individuals, respectively). Fisher’s ex-
act test was used to determinewhether hypermethylation
of H19 was associated with IH and BWS. A P value
!.05 was considered statistically signiﬁcant.
We received samples from 24 patients with IH and
Wilms tumor. On the basis of chart review, we excluded
the diagnosis of IH for a total of 7 of the 24 patients.
Six excluded patients had been initially classiﬁed as hav-
ing IH but also had one or two of the cardinal features
of BWS: macroglossia and macrosomia ( ), ma-np 1
croglossia and umbilical hernia ( ), umbilical her-np 1
nia alone ( ), or macrosomia alone ( ). Thesenp 1 np 3
patients were excluded because of the ambiguity of the
clinical diagnosis and because they had not previously
received a diagnosis of BWS. One patient was excluded
for suspected neuroﬁbromatosis because of cafe´ au lait
pigmentation. The remaining 17 patients received the
diagnosis of IH.
We received samples from 16 patients with BWS and
Wilms tumor. When available, records of congenital
anomalies and birth weight were assessed to conﬁrm the
diagnosis (table 1). Gestational ages were not available
to determine whether the patient had macrosomia, de-
ﬁned as birth weight 90th percentile.
We tested normal kidney tissue for methylation status
at H19 and LIT1 and typed the normal and tumor tis-
sues for microsatellite markers at 11p15 to identify UPD
or LOH (ﬁgs. 1 and 2 and tables 2 and 3). If no normal
tissue was available, we analyzed the methylation and
microsatellites of the tumor tissue. We accepted the tu-
mor data as representative of the state of the normal
Reports 889
Figure 2 Analysis of LIT1 methylation in patients with BWS
and IH. An EST probe from the LIT1 gene was hybridized to genomic
DNA digested with BamH1 and the methylcytosine-sensitive restric-
tion enzyme NotI. The upper band represents the 6.0-kb unmethylated
fragment, and the lower band represents the 4.2-kb unmethylated di-
gested fragment. Patient numbers corresponding to those in the tables
are shown below the lanes. All DNA specimens were from the normal
kidney except samples for IH13, IH14, and IH17, which were from
the Wilms tumor. fk p fetal kidney.
Table 2
Molecular Analysis of Kidney Tissue from Patients with IH and Wilms Tumor
PATIENT
NORMAL KIDNEY TISSUE TUMOR KIDNEY TISSUE
NOTE
H19
Methylation
LIT1
Methylation
Microsatellite
Analysis
H19
Methylation
LIT1
Methylation
Microsatellite
Analysis
IH1 Normal Normal Normal … … Normal …
IH2 Normal Normal Normal … … Normal …
IH3 Normal Normal Normal … … Normal …
IH4 Normal Normal Normal … … LOH …
IH5 Normal Normal Normal … … LOH …
IH6 Abnormal Normal Normal … … Normal …
IH7 Abnormal Abnormal UPD … … … …
IH8 Normal Normal Normal … … … …
IH9 Normal Normal Normal … … … …
IH10 … … … Normal Normal Normal …
IH11 Normal Normal Normal … … LOH …
IH12 Abnormal Abnormal UPD … … … …
IH13 … … … Normal Normal Normal …
IH14 … … … Normal Normal Normal …
IH15 … … … Normal Normal Normal …
IH16 … … … Abnormal Normal Normal Excludeda
IH17 … … … Abnormal Abnormal LOH or UPD? Excludedb
a Patient IH16 was excluded because it was not possible to determine whether the hypermethylation of H19 in the
tumor was constitutive or tumor speciﬁc.
b Patient IH17 was excluded because it was not possible to determine whether multiple homozygous microsatellite
markers were due to LOH or UPD.
tissue if the tumor had the half methylation pattern that
occurs in normal tissues and showed retention of het-
erozygosity by microsatellite analysis (patients IH10,
IH13, IH14, and IH15). The assumption is that if tumor
tissue from a particular sample shows normal methyl-
ation of H19 or heterozygosity, the corresponding nor-
mal tissue will not show hypermethylation or homo-
zygosity, respectively. This assumption was reasonable
and necessary because, for four samples, only tumor
tissue was available. We tested this assumption in six
patients (patients BWS1, BWS2, BWS3, BWS10, BWS11,
and BWS16) by examining the methylation status of
paired tumors and normal kidneys, which all showed
abnormal methylation. In all cases, both the tumor tissue
and the normal kidney tissue showed abnormal meth-
ylation. These data support the concept that normal
methylation of H19 in the tumor does not occur when
there is abnormal H19 methylation in the normal tissue.
There is no mechanism for acquisition of heterozygosity
at multiple microsatellite markers, other than microsat-
ellite instability, which is rare in Wilms tumor (Mason
et al. 2000), and the pattern of heterozygosity observed
was not that seen in microsatellite instability—that is,
with narrowly spaced alleles. We excluded patients in
whom the tumor was the only available sample and had
abnormal methylation (patients IH16 and BWS13), be-
cause we could not determine whether the normal tissue
had normal or abnormal methylation. When available,
we also tested patient blood genomic DNA to provide
convincing evidence of UPD and LOH and tested pa-
rental blood genomic DNA to identify the parental or-
igin of microsatellite alleles. For one patient, although
kidney tissue was not available, patient and parental
blood genomic DNA was available for analysis (patient
BWS9). The ﬁnding of UPD in the patient’s blood sample
made the testing of other tissues unnecessary.
The majority of children with IH had a normal hemi-
methylated pattern of H19 and LIT1. Molecular anal-
yses of the 15 evaluable patients with IH (table 2) in-
dicated that 12 patients had normal methylation of H19
and LIT1. Of these 12, 4 had LOH of 11p15 (patients
IH3, IH4, IH5, and IH11), 6 did not have LOH (patients
IH1, IH2, IH10, IH13, IH14, IH15), and 2 did not have
tumor tissue available to test for LOH (patients IH8 and
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Table 3
Molecular Analysis of Kidney Tissue from Patients with BWS and Wilms Tumor
PATIENT
NORMAL KIDNEY TISSUE TUMOR KIDNEY TISSUE
NOTE
H19
Methylation
LIT1
Methylation
Microsatellite
Analysis
H19
Methylation
LIT1
Methylation
Microsatellite
Analysis
BWS1 Abnormal Normal Normal Abnormal Normal Normal …
BWS2 Abnormal Normal Normal Abnormal Normal Normal …
BWS3 Abnormal Normal Normal Abnormal Normal Normal …
BWS4 Abnormal Abnormal UPD … … … …
BWS5 Abnormal Abnormal UPD … … … …
BWS6 Abnormal Abnormal UPD … … … …
BWS7 Abnormal Abnormal UPD … … … …
BWS8 Normal Abnormal Normal … … LOH …
BWS9 … … … … … … UPD in blood
BWS10 Abnormal Normal Normal Abnormal Normal Normal …
BWS11 Abnormal Normal Normal Abnormal Normal Normal …
BWS12 Normal Abnormal Normal … … LOH …
BWS13 … … … Abnormal Abnormal Normal Excludeda
BWS14 … … … Abnormal Abnormal LOH or UPD? Excludedb
BWS15 Normal Normal Normal … … LOH …
BWS16 Abnormal Normal Normal Abnormal Normal Normal …
a Patient BWS13 was excluded because it was not possible to determine whether the hypermethylation of H19 and LIT1
in the tumor was constitutive or tumor speciﬁc.
b Patient BWS14 was excluded because it was not possible to determine whether multiple homozygous microsatellite
markers were due to LOH or UPD.
IH9). Three patients had an abnormal methylation pat-
tern in H19, one patient had hypermethylation of H19
in the normal kidney tissue and retention of heterozy-
gosity in the tumor (patient IH6), and two patients had
constitutive UPD (patients IH7 and IH12).
Unlike the children with IH and Wilms tumor, the
majority of children with BWS and Wilms tumor had
abnormal methylation patterns of H19 or LIT1. Mo-
lecular analyses of 14 evaluable patients with BWS (table
3) indicated that 13 of them had abnormal methylation
of either H19 or LIT1. Six children had hypermethy-
lation of H19 alone, with retention of heterozygosity
in the tumor (patients BWS1, BWS2, BWS3, BWS10,
BWS11, and BWS16). Five patients had constitutive
UPD (patients BWS4, BWS5, BWS6, BWS7, and BWS9)
that included abnormal methylation in H19 and LIT1,
and two patients had hypomethylation of LIT1 and
LOH in the tumor (patients BWS8 and BWS12). One
patient had normal methylation of H19 and LIT1 and
LOH in the tumor (patient BWS15).
The frequency of hypermethylation of H19 in children
with IH and Wilms tumor, 20% (3/15), was signiﬁcantly
lower than the frequency in children with BWS and
Wilms tumor, 79% (11/14; ) (table 4). In ad-Pp .0028
dition, this difference between IH and BWS remained
signiﬁcant when patients with UPD for 11p15, which
encompasses H19 along with many other genes, were
excluded: hypermethylation frequencies of 67% (6/9)
and 8% (1/13) for IH and BWS, respectively (Pp
) (table 4)..0066
The higher proportion of abnormal methylation of
H19 in patients with BWS and Wilms tumor corrobo-
rated our previous results in the BWS Registry and was
expected (DeBaun et al. 2002). Given the signiﬁcant
overlap between BWS and IH, we did not expect the
low frequency of H19 methylation abnormalities in the
patients with IH and Wilms tumor.
Several possibilities exist as to why the children with
IH and Wilms tumor did not have the expected epige-
netic abnormalities. Perhaps children with IH andWilms
tumor are genetically different from children with IH
and without Wilms tumor. Alternatively, patients with
IH may have a different genotype that acts in a common
causal pathway and results in a similar phenotype to
that of BWS. The rare cases of IH with UPD of 11p15.5,
described here and by others (Grundy et al. 1991), sug-
gest that there might be another gene on 11p15.5 in-
cluded in the disomic region that is responsible for the
phenotype.
An unexpected ﬁnding was LOH of 11p15.5 inWilms
tumors from patients with BWS. Speciﬁcally, three tu-
mors from patients with BWS showed LOH; two arose
in patients with hypomethylation of LIT1. In addition,
four tumors from patients with IH were determined to
have LOH, all arising in patients without any known
epigenetic alteration. These data are consistent with a
model we have proposed in which epigenetic alterations
(hypermethylation of LIT1, in this case) represent the
ﬁrst “hit” in Knudson’s two-hit model, and subsequent
genetic changes represent the second hit (Feinberg and
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Table 4
Signiﬁcant Difference in Frequency of Hypermethylation of H19 in BWS
and IH
Sample Tested
and Patient Group
Hypermethylation
of H19 (%) Normal H19 (%)
Entire samplea:
Patients with BWS 11/14 (79) 3/14 (21)
Patients with IH 3/15 (20) 12/15 (80)
Sample excluding UPD for 11p15b:
Patients with BWS 6/9 (67) 3/9 (33)
Patients with IH 1/13 (8) 12/13 (92)
a for hypermethylation values.Pp .0028
b for hypermethylation values.Pp .0066
Tycko 2004). Knudson’s hypothesis does not require al-
lelism for the two hits, and, by our modiﬁed Knudson
model, epigenetic alterations can lead to an expanded
population of precursor cells that are targets for sub-
sequent oncogenetic activation, thereby increasing the
risk of malignancy in the presence of constitutional epi-
genetic alterations in BWS.
In summary, children with IH and Wilms tumor do
not have the constitutional hypermethylation of H19
that is associated with cancer, unlike those with BWS,
in which cancer is associated with constitutional hyper-
methylation of H19.
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Web Resources
The URL for data presented herein is as follows:
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.ncbi.nlm.gov/Omim/ (for BWS and IH)
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